Frontiers in cellular and infection microbiology · 2025
Single-cell transcriptome profile during the antibody decline phase following inactivated COVID-19 vaccination.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhu Zhongyi, Huang Yaling, Sun Jiatong, Li Meirong, Chen Yong, Huang Fubaoqian, Liu Chuanyu, Chen Weijun, Ma Jinmin
Аннотация
INTRODUCTION: Variability in antibody responses among individuals following vaccination is a common phenomenon. This study employs single-cell transcriptome sequencing to characterize the transcriptomic features underlying these variations during the antibody decline phase after inactivated COVID-19 vaccination.
METHODS: Sixty-five healthy volunteers received two doses of BBIBP-CorV. Antibody levels were measured 109-140 days post-vaccination. From these, 15 samples representing low, median, and high antibody titers were selected for PBMC single-cell RNA sequencing.
RESULTS: Re-analysis of antibody kinetics revealed that titers during the decline phase are most strongly associated with long-term persistence. Differentially expressed genes were enriched in immune pathways including lymphocyte activation, antigen presentation (MHC-I and MHC-II), and interferon signaling. Significant variation in HLA genes, particularly HLA-B, was observed across PBMC cell types. Cell-cell communication analysis further identified enhanced MHC-I signaling in high-titer groups, dominated by HLA-B interactions with CD8+ T cells.
DISCUSSION: These findings reveal a state of balanced immune alertness during the decline phase, providing insights into the cellular and molecular determinants of long-term humoral immunity and informing future vaccine design.
METHODS: Sixty-five healthy volunteers received two doses of BBIBP-CorV. Antibody levels were measured 109-140 days post-vaccination. From these, 15 samples representing low, median, and high antibody titers were selected for PBMC single-cell RNA sequencing.
RESULTS: Re-analysis of antibody kinetics revealed that titers during the decline phase are most strongly associated with long-term persistence. Differentially expressed genes were enriched in immune pathways including lymphocyte activation, antigen presentation (MHC-I and MHC-II), and interferon signaling. Significant variation in HLA genes, particularly HLA-B, was observed across PBMC cell types. Cell-cell communication analysis further identified enhanced MHC-I signaling in high-titer groups, dominated by HLA-B interactions with CD8+ T cells.
DISCUSSION: These findings reveal a state of balanced immune alertness during the decline phase, providing insights into the cellular and molecular determinants of long-term humoral immunity and informing future vaccine design.